nach oben

Erschienen in:

01.03.2013 | Original Article

Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites

verfasst von: Hidenori Tamegai, Teruo Kaiga, Mitsugu Kochi, Masashi Fujii, Noriaki Kanamori, Yoshiaki Mihara, Tomoya Funada, Hiroko Shimizu, Daijo Jinno, Tadatoshi Takayama

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to investigate whether intravenous (i.v.) administration allowed docetaxel to penetrate ascites in gastric cancer patients with peritoneal dissemination.

Patients and methods

Twelve patients with disseminated gastric carcinoma were enrolled in the study. All patients received docetaxel-containing drug regimens: i.v. administration of 40 mg/m² docetaxel in 6 patients, and 60 mg/m² in the remainder. Docetaxel concentrations in the plasma and ascites were measured.

Results

Docetaxel was detected in the ascites of 4 patients in the 40 mg/m² group and 5 patients in the 60 mg/m² group. The highest concentration of docetaxel in plasma was detected at immediately after administration (median: 1,660 ng/mL, 501–2,560 ng/mL), after which it gradually decreased. The highest concentration of docetaxel in ascites was observed at ~7 h after administration and varied among cases (median: 18 ng/mL, 11–52 ng/mL).

Conclusion

Intravenous administration allows to penetrate ascites in gastric cancer patients with peritoneal dissemination.

Kim YH, Koizumi W, Lee KH, Kishimoto T, Chung HC, Hara T, Cho JY, Nakajima T, Kim H, Fujii M (2011) Randomized phase III study of S-1 alone versus S-1 + docetaxel in the treatment for advanced gastric cancer (The START trial) ASCO-GI 2011 gastrointestinal cancers symposium oral abstract session abstract #7

Eguchi T, Fujii M, Wakabayashi K, Aisaki K, Tsuneda Y, Kochi M, Takayama T (2003) Docetaxel plus 5-fluorouracil for terminal gastric cancer patients with peritoneal dissemination. Hepatogastroenterology 50:1735–1738PubMed

Markman M, Zanotti K, Webster K, Peterson G, Kulp B, Belinson J (2003) Phase 2 trial of single agent docetaxel in platinum and paclitaxel refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol 91(3):573–576PubMedCrossRef

Díaz JF, Andreu JM (1993) Assembly of purified GDP-tubulin into microtubules induced by taxol and Taxotere: reversibility, ligand stoichiometry and competition. Biochemistry 32:2747–2755PubMedCrossRef

Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, Scottish Gynaecological Cancer Trials Group (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682–1691PubMedCrossRef

Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402–3407PubMedCrossRef

Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M et al (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17(5):1413–1424PubMed

Debernardis D, Siré EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D’Incalci M, Broggini M (1997) p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57(5):870–874PubMed

Vergniol JC, Bruno R, Montay G, Frydman A (1992) Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582(1–2):273–278PubMed

10.

Sugarbaker PH, Stuart OA, Vjdal-Jove J et al (1993) Studies of the peritoneal-plasma barrier after systemic mitomycin C administration. Reg Cancer Treat 4:188–194

11.

Shimada T, Nomura M, Yokogawa K, Endo Y, Sasaki T, Miyamoto K, Yonemura Y (2005) Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. J Pharm Pharmacol 57(2):177–181PubMedCrossRef

12.

Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH (2002) Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol 49(6):499–503PubMedCrossRef

13.

Naitoh H, Kawaguch A, Yamamoto H, Mekata E, Tan T, Morii H, Chiba M (2004) Measurement of docetaxel concentration in blood and ascites after drip infusion into each vessel and intraperitoneal cavity of gastric cancer. Gan To Kagaku Ryoho 31(12):2031–2034PubMed

14.

Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl J Med 335(26):1950–1955PubMedCrossRef

15.

Vlasveld LT, Gallee MP, Rodenhuis S, Taal BG (1991) Intraperitoneal chemotherapy for malignant peritoneal mesothelioma (1991). Eur J Cancer 27(6):732PubMedCrossRef

16.

Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228(3):347–354PubMedCrossRef

17.

Tanaka M, Obata T, Sasaki T (1996) Evaluation of antitumour effects of docetaxel (Taxotere^®) on human gastric cancers in vitro and in vivo. Eur J Cancer 32A(2):226–230PubMedCrossRef

Titel: Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites
verfasst von: Hidenori Tamegai
Teruo Kaiga
Mitsugu Kochi
Masashi Fujii
Noriaki Kanamori
Yoshiaki Mihara
Tomoya Funada
Hiroko Shimizu
Daijo Jinno
Tadatoshi Takayama
Publikationsdatum: 01.03.2013
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2013
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-2066-9

Springer Medizin

Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites